[A19-20] Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68
Last updated 04.04.2019
Commission awarded on 25.03.2019 by the Federal Joint Committee (G-BA).
Head and nerves
Vitreomacular traction, including when associated with macular hole of diameter ≤ 400 microns
Conclusion of dossier assessment A18-68 unchanged
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
|A18-68||Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)||Commission completed|